Data published in JAMA Network Open suggest that prescribing practices of antiretroviral therapy (ART) in pregnant women living with HIV in the United States do not align optimally with national guidelines. In this prospective cohort study including data from 1867 pregnancies in 1582 women living with HIV, 49.5% were associated with prescribed ART designated as…
Starting antiretroviral therapy (ART) for HIV-infected infants within hours of birth does not seem to result in a higher proportion of infants who attain and sustain viral suppression on ART.
An evaluation of the FDA program to review antiretroviral drugs for use in low-resource settings, conducted by the PEPFAR, showed that the FDA’s efforts have made many HIV drugs available for use globally.
The implications of expanding HIV pre-exposure prophylaxis coverage in men who have sex with men on sexually transmitted infection epidemics vary depending on the benefit to the individual or the population.
The NDA for a first-in-class HIV-1 attachment inhibitor for the treatment of HIV-1 infection has been submitted to the FDA.
Although the prevalence of distal sensory peripheral neuropathy decreased following initiation of cART in people living with in resource-limiting settings, better strategies are needed.
Expanding access to PrEP is key part of government’s aim of ending nation’s HIV epidemic by 2030
Maternal efavirenz use tied to increased risk among children who are HIV-exposed but uninfected
Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points.
The FDA as approved updated labeling for all efavirenz-containing products with additions to the Warnings and Precautions and Adverse Reactions: Postmarketing Experience sections.
